Skip to main content
GLUE
NASDAQ Life Sciences

Versant Funds Significantly Reduce Stake in Monte Rosa Therapeutics

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
8
Price
$24.47
Mkt Cap
$1.581B
52W Low
$3.5
52W High
$25.77
Market data snapshot near publication time

Summary

Versant Venture Capital and related funds have significantly reduced their aggregate ownership in Monte Rosa Therapeutics, Inc. from 7.54% to 4.99% through a combination of share sales and pro rata distributions to limited partners.


Key Events

  • Significant Stake Reduction

    Versant Venture Capital VI, L.P. and Versant Vantage I, L.P., along with their affiliated entities, collectively reduced their ownership from approximately 7.54% to 4.99% of Monte Rosa Therapeutics' common stock.

  • Substantial Share Dispositions

    The reduction involved the disposition of 1,658,053 shares, valued at over $40 million based on the current stock price.

  • Combination of Sales and Distributions

    The disposition included open market sales totaling over $13 million and pro rata distributions of shares to the funds' limited partners.

  • Institutional Investor Exit

    This significant reduction in holdings by a major institutional investor may indicate a re-evaluation of the investment or a strategic portfolio adjustment.


Analysis

This Schedule 13D/A filing indicates a substantial reduction in the aggregate holdings of Versant Venture Capital and its affiliated funds in Monte Rosa Therapeutics. The funds decreased their stake from approximately 7.54% to 4.99% of outstanding common stock, representing a disposition of over $40 million in shares. While some shares were sold on the open market for proceeds exceeding $13 million, a significant portion was distributed pro rata to limited partners. This overall reduction in ownership by a major institutional investor could signal a shift in investment strategy or reduced conviction in the company's future prospects. Investors should monitor future filings for further changes in institutional ownership.

At the time of this filing, GLUE was trading at $24.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.50 to $25.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GLUE - Latest Insights

GLUE
Jun 01, 2026, 4:29 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $19.67
Real-time Price: $18.30 info
Change: -$1.37 (-7%) info
Market Cap: $1.54B info
GLUE
May 07, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.33
Real-time Price: $18.30 info
Change: -$2.03 (-10%) info
Market Cap: $1.54B info
GLUE
May 07, 2026, 7:28 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $20.35
Real-time Price: $18.30 info
Change: -$2.05 (-10%) info
Market Cap: $1.54B info
GLUE
May 07, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.35
Real-time Price: $18.30 info
Change: -$2.05 (-10%) info
Market Cap: $1.54B info
GLUE
May 01, 2026, 4:53 PM EDT
Filing Type: 144
Importance Score:
10
Price at Filing: $18.80
Real-time Price: $18.30 info
Change: -$0.500 (-3%) info
Market Cap: $1.54B info
GLUE
Mar 17, 2026, 7:14 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $15.87
Real-time Price: $18.30 info
Change: +$2.43 (+15%) info
Market Cap: $1.54B info
GLUE
Mar 17, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.87
Real-time Price: $18.30 info
Change: +$2.43 (+15%) info
Market Cap: $1.54B info
GLUE
Mar 17, 2026, 7:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $15.87
Real-time Price: $18.30 info
Change: +$2.43 (+15%) info
Market Cap: $1.54B info
GLUE
Mar 16, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.40
Real-time Price: $18.30 info
Change: +$1.90 (+12%) info
Market Cap: $1.54B info
GLUE
Feb 11, 2026, 4:36 PM EST
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $18.96
Real-time Price: $18.30 info
Change: -$0.660 (-3%) info
Market Cap: $1.54B info